• Home
  • Pharmaceuticals and Healthcare
Global Sterile Intravenous (IV) Solution Industry Outlook 2021: Overview, Opportunities, Key Companies and Forecast to 2027

Global Sterile Intravenous (IV) Solution Industry Outlook 2021: Overview, Opportunities, Key Companies and Forecast to 2027

Report Code: KNJ917636 | No. of Pages: 102 | Category: Pharmaceuticals and Healthcare
Publisher: GRD Survey | Date of Publish: Sep-2021 
Executive Summary

According to GRD Survey data, the global Sterile Intravenous (IV) Solution market was valued at  million US$ in 2020 and is expected to  million US$ by the end of 2027, growing at a CAGR of % in the forecast period 2021 and 2027.

This report studies the Sterile Intravenous (IV) Solution market dynamics from angles such as new entries, mergers and acquisitions, fundings, exit and major technology breakthroughs. Market performance is evaluated through market size (Million USD) by players, regions, product types and end industries. This report also studies the global market competition landscape, market drivers and trends, opportunities and challenges, risks and entry barriers, sales channels, distributors and Porter's Five Forces Analysis.

Geographically, this report is segmented into several key regions, with revenue, market share and growth Rate of Sterile Intravenous (IV) Solution in these regions, from 2016 to 2027, covering
    North America (United States, Canada and Mexico)
    Europe (Germany, France, UK, Italy, Spain and Russia, etc.)
    Asia-Pacific (China, Japan, Korea, Southeast Asia, India, Australia)
    South America (Brazil, Argentina, Colombia, etc.)
    Middle East and Africa (Turkey, Saudi Arabia, South Africa, etc.)

Market Snapshot, By Product Type
    Crystalloids

    Colloids

    Others

Market Snapshot, By Application
    Medications

    NutritionNutrition

    Blood-based Products

    Others

Market Snapshot, By Region:
    North America
        United States
        Canada
        Mexico
    Europe
        Germany
        France
        UK
        Italy
        Russia
        Spain
    Asia Pacific
        China
        Japan
        Korea
        Southeast Asia
        India
        Australia
    Central & South America
        Brazil
        Argentina
        Colombia
    Middle East & Africa
        Iran
        South Africa
        Israel
        Turkey
        Saudi Arabia

Main Market Players Analyzed in this report, including:
    Xi'an Libang Alliance Enterprise Management

    Wallcur

    Technoflex

    Mckesson

    Livzon Group

    Jiangsu Hengfengqiang Biotechnology

    Jiangsu Hengfengqiang Biotechnology

    ICU Medical, Inc

    Hospira

    Hospira

    Hebei Guangren Pharmaceutical Technology

    Baxter International

    B. Braun Medical Inc.

    Amsino


The study objectives of this report are:
    To study and analyze the global Sterile Intravenous (IV) Solution market size (Million USD) by company, key regions/countries, products and application, history data from 2016 to 2020, and forecast to 2027.
    To understand industry structure of Sterile Intravenous (IV) Solution market by identifying its various subsegments.
    To share detailed information about the key factors influencing the growth of the market (growth potential, opportunities, drivers, industry-specific challenges and risks).
    To identify the key global Sterile Intravenous (IV) Solution manufacturers and regional typical players, to define, describe and analyze their sales volume, value, market share, market competition landscape, SWOT analysis and development plans in next few years.
    To analyze the Sterile Intravenous (IV) Solution market with respect to individual growth trends, future prospects, and their contribution to the total market.
    To project the value and volume of Sterile Intravenous (IV) Solution submarkets, with respect to key regions (along with their respective key countries).
    To analyze competitive developments such as expansions, agreements, new product launches, and acquisitions in the market.
    To strategically profile the key players and comprehensively analyze their growth strategies.

In this study, the years considered to estimate the market size of Sterile Intravenous (IV) Solution are as follows:
    History Year: 2016-2020
    Base Year: 2020
    Estimated Year: 2021
    Forecast Year 2021 to 2027

This report includes the estimation of market size from top-down approach by analyzing major submarkets and their major driving factors, and verified from bottom-up approaches. Key players in the market have been identified through secondary research, and their market shares have been determined through primary and secondary research. All percentage shares, splits, and breakdowns have been determined using secondary sources and verified from primary sources.

For the data information by region, company, type and application, 2020 is considered as the base year. Whenever data information was unavailable for the base year, the prior year has been considered.

Key Stakeholders Considered in the study:
Raw material vendors
Distributors/traders/wholesalers/suppliers
Regulatory authorities, including government agencies and NGO
Commercial research & development (R&D) institutions
Importers and exporters
Government organizations, research organizations, and consulting firms
Trade/Industrial associations
End-use industries

Table of Contents

1  Market Definition & Scope
    1.1  Definition & Scope
    1.2 Sterile Intravenous (IV) Solution Product Specifications
    1.3  Main Events (Entry, M&A, Exit, Technology and Capital Activity)
    1.4 Global Sterile Intravenous (IV) Solution Market Performance and Outlook

2 Market Development Performance under COVID-19
    2.1 Influencing Factors of Industry Development in the Next Five Years
        2.1.1 Drivers
        2.1.2 Restraints
        2.1.3 Opportunities
    2.2 Porter’s Five Forces Analysis
    2.3 Comparison of Alternatives and Sterile Intravenous (IV) Solution

3 3 Industrial Lift Cycle and Main Buyers Analysis
    3.1 Industry Life Cycle Analysis
    3.2 Key Buying Industries/Consumers
        3.2.1 Major Buyers in Medications

        3.2.2 Major Buyers in NutritionNutrition


4 Market Segment: by Type
    4.1 Sterile Intravenous (IV) Solution Type Introduction
        4.1.1 Crystalloids

        4.1.2 Colloids

        4.1.3 Others
    4.2 Global Sterile Intravenous (IV) Solution Revenue by Type 2016-2021

5 Market Segment: by Application
    5.1 Sterile Intravenous (IV) Solution Type Introduction
        5.1.1 Medications

        5.1.2 NutritionNutrition

        5.1.3 Blood-based Products

        5.1.3 Others
    5.2 Global Sterile Intravenous (IV) Solution Revenue by Application 2016-2021

6 Marke Segment: by Region
    6.1 Global Sterile Intravenous (IV) Solution Market by Region
    6.2 North America Sterile Intravenous (IV) Solution Market 2016-2021
    6.3 Europe Sterile Intravenous (IV) Solution Market 2016-2021
    6.4 Asia Pacific Sterile Intravenous (IV) Solution Market 2016-2021
    6.5 South America Sterile Intravenous (IV) Solution Market 2016-2021
    6.6 Middle East and Africa Sterile Intravenous (IV) Solution Market 2016-2021

7 North America
    7.1 North America Sterile Intravenous (IV) Solution Market by Country 2016-2021
    7.2 United States
    7.3 Canada
    7.4 Mexico

8 Europe
    8.1 Europe Sterile Intravenous (IV) Solution Market by Country 2016-2021
    8.2 Germany
    8.3 France
    8.4 UK
    8.5 Italy
    8.6 Russia
    8.7 Spain

9 Asia Pacific
    9.1 Asia Pacific Sterile Intravenous (IV) Solution Market by Country 2016-2021
    9.2 China
    9.3 Japan
    9.4 Korea
    9.5 Southeast Asia
    9.6 India
    9.7 Australia

10 South America
    10.1 South America Sterile Intravenous (IV) Solution Market by Country 2016-2021
    10.2 Brazil
    10.3 Argentina
    10.4 Colombia

11 Middle East and Africa
    11.1 Middle East and Africa Sterile Intravenous (IV) Solution Market by Country 2016-2021
    11.2 Turkey
    11.3 Saudi Arabia
    11.4 South Africa

12 Key Participants Company Information
    12.1 Xi'an Libang Alliance Enterprise Management

        12.1.1 Xi'an Libang Alliance Enterprise Management
 Company Information
        12.1.2 Xi'an Libang Alliance Enterprise Management
 Sterile Intravenous (IV) Solution Product Portfolio, Specification and Application
        12.1.3 Xi'an Libang Alliance Enterprise Management
 Sterile Intravenous (IV) Solution Revenue and Gross Margin (2019-2021)
        12.1.4 Xi'an Libang Alliance Enterprise Management
 Key Development
    12.2 Wallcur

        12.2.1 Wallcur
 Company Information
        12.2.2 Wallcur
 Sterile Intravenous (IV) Solution Product Portfolio, Specification and Application
        12.2.3 Wallcur
 Sterile Intravenous (IV) Solution Revenue and Gross Margin (2019-2021)
        12.2.4 Wallcur
 Key Development
    12.3 Technoflex

        12.3.1 Technoflex
 Company Information
        12.3.2 Technoflex
 Sterile Intravenous (IV) Solution Product Portfolio, Specification and Application
        12.3.3 Technoflex
 Sterile Intravenous (IV) Solution Revenue and Gross Margin (2019-2021)
        12.3.4 Technoflex
 Key Development
    12.4 Mckesson

        12.4.1 Mckesson
 Company Information
        12.4.2 Mckesson
 Sterile Intravenous (IV) Solution Product Portfolio, Specification and Application
        12.4.3 Mckesson
 Sterile Intravenous (IV) Solution Revenue and Gross Margin (2019-2021)
        12.4.4 Mckesson
 Key Development
    12.5 Livzon Group

        12.5.1 Livzon Group
 Company Information
        12.5.2 Livzon Group
 Sterile Intravenous (IV) Solution Product Portfolio, Specification and Application
        12.5.3 Livzon Group
 Sterile Intravenous (IV) Solution Revenue and Gross Margin (2019-2021)
        12.5.4 Livzon Group
 Key Development
    12.6 Jiangsu Hengfengqiang Biotechnology

        12.6.1 Jiangsu Hengfengqiang Biotechnology
 Company Information
        12.6.2 Jiangsu Hengfengqiang Biotechnology
 Sterile Intravenous (IV) Solution Product Portfolio, Specification and Application
        12.6.3 Jiangsu Hengfengqiang Biotechnology
 Sterile Intravenous (IV) Solution Revenue and Gross Margin (2019-2021)
        12.6.4 Jiangsu Hengfengqiang Biotechnology
 Key Development
    12.7 Jiangsu Hengfengqiang Biotechnology

        12.7.1 Jiangsu Hengfengqiang Biotechnology
 Company Information
        12.7.2 Jiangsu Hengfengqiang Biotechnology
 Sterile Intravenous (IV) Solution Product Portfolio, Specification and Application
        12.7.3 Jiangsu Hengfengqiang Biotechnology
 Sterile Intravenous (IV) Solution Revenue and Gross Margin (2019-2021)
        12.7.4 Jiangsu Hengfengqiang Biotechnology
 Key Development
    12.9 Hospira

        12.9.1 Hospira
 Company Information
        12.9.2 Hospira
 Sterile Intravenous (IV) Solution Product Portfolio, Specification and Application
        12.9.3 Hospira
 Sterile Intravenous (IV) Solution Revenue and Gross Margin (2019-2021)
        12.9.4 Hospira
 Key Development
    12.8 ICU Medical, Inc

        12.8.1 ICU Medical, Inc
 Company Information
        12.8.2 ICU Medical, Inc
 Sterile Intravenous (IV) Solution Product Portfolio, Specification and Application
        12.8.3 ICU Medical, Inc
 Sterile Intravenous (IV) Solution Revenue and Gross Margin (2019-2021)
        12.8.4 ICU Medical, Inc
 Key Development
    12.11 Hebei Guangren Pharmaceutical Technology

        12.11.1 Hebei Guangren Pharmaceutical Technology
 Company Information
        12.11.2 Hebei Guangren Pharmaceutical Technology
 Sterile Intravenous (IV) Solution Product Portfolio, Specification and Application
        12.11.3 Hebei Guangren Pharmaceutical Technology
 Sterile Intravenous (IV) Solution Revenue and Gross Margin (2019-2021)
        12.11.4 Hebei Guangren Pharmaceutical Technology
 Key Development
    12.12 Baxter International

        12.12.1 Baxter International
 Company Information
        12.12.2 Baxter International
 Sterile Intravenous (IV) Solution Product Portfolio, Specification and Application
        12.12.3 Baxter International
 Sterile Intravenous (IV) Solution Revenue and Gross Margin (2019-2021)
        12.12.4 Baxter International
 Key Development
    12.13 B. Braun Medical Inc.

        12.13.1 B. Braun Medical Inc.
 Company Information
        12.13.2 B. Braun Medical Inc.
 Sterile Intravenous (IV) Solution Product Portfolio, Specification and Application
        12.13.3 B. Braun Medical Inc.
 Sterile Intravenous (IV) Solution Revenue and Gross Margin (2019-2021)
        12.13.4 B. Braun Medical Inc.
 Key Development
    12.14 Amsino

        12.14.1 Amsino
 Company Information
        12.14.2 Amsino
 Sterile Intravenous (IV) Solution Product Portfolio, Specification and Application
        12.14.3 Amsino
 Sterile Intravenous (IV) Solution Revenue and Gross Margin (2019-2021)
        12.14.4 Amsino
 Key Development

13 Global Sterile Intravenous (IV) Solution Market Forecast by Region by Type and by Application
    13.1 Global Sterile Intravenous (IV) Solution Revenue Forecast 2022-2027
    13.2 Global Sterile Intravenous (IV) Solution Forecast by Regions
    13.3 Global Sterile Intravenous (IV) Solution Forecast by Type
    13.4 Global Sterile Intravenous (IV) Solution Forecast by Application

14 Analyst Views and Conclusions
15 Methodology and Data Source
    15.1 Methodology
    15.2 Research Data Source
        15.2.1 Secondary Data
        15.2.2 Primary Data
        15.2.3 Market Size Estimation
    15.3 Legal Disclaimer

NEED Help?

If you need any help or guidance, please feel free to call us.

USA : +1 (661) 636 6162

INDIA : +91 9325802062

or

Write us on : sales@kandjmarketresearch.com